- Start date
- 22 Jun 2024
- End date
- 22 Jun 2024
- Location
- Auditorium
Programme
12:20
Welcome and introduction
Frederik Marmé, Mannheim, Germany
12:25
Insights in the biology of ovarian cancer: The neglected pathways
Frederik Marmé, Mannheim, Germany
12:37
A clinical case of a patient with platinum-resistant ovarian cancer: Resistance mechanisms and state-of-the-art treatment options for patients who are not eligible for platinum-based therapies
Nicoletta Colombo, Milan, Italy
12:49
The promise of antibody drug conjugates (ADCs) in ovarian cancer: Mechanisms of action and emerging therapeutics
Toon Van Gorp, Leuven, Belgium
13:01
A clinical case of a patient on anti-folate receptor ADC: Efficacy and safety data from folate receptor targeting in registrational trials
Kathleen Moore, Oklahoma City, OK, USA
13:13
Q&A, discussion and concluding remarks
Nicoletta Colombo, Milan, Italy
Learning objectives
- To provide insights on the biological pathways involved in ovarian carcinogenesis and in the mechanisms of primary resistance to platinum-based therapies
- To inform on the state-of-the-art management of patients with platinum-resistant ovarian cancer
- To share knowledge about novel and emerging treatment options based on antibody drug conjugates (ADCs) for patients with relapsed ovarian cancer
